Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Capivasertib

FDA-approved product (tablet, oral), marketed as Truqap.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Capivasertib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast neoplasm
  • Cancer
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Other protein kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Capivasertib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Capivasertib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

    NCT05720260 · start 2023-01-17

    Registered record
    Registry ID
    NCT05720260
    Conditions
    Premenopausal Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer
    Interventions
    Goserelin; Fulvestrant; Capivasertib; Durvalumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-01-17
    Completion
    2027-01-31
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPremenopausal Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer
    InterventionGoserelin; Fulvestrant; Capivasertib; Durvalumab
    PhasePhase 2
    Registry statusRecruiting

  • Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

    NCT05455619 · start 2022-08-26

    Registered record
    Registry ID
    NCT05455619
    Conditions
    HR+/HER2-negative Breast Cancer; Metastatic Breast Cancer
    Interventions
    Evexomostat
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2022-08-26
    Completion
    2027-03
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHR+/HER2-negative Breast Cancer; Metastatic Breast Cancer
    InterventionEvexomostat
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • A Study to Investigate the Absolute Bioavailability, Absorption, Metabolism, Distribution and Excretion of [14C]AZD5363 (Capivasertib)

    NCT05419401 · start 2022-04-11

    Registered record
    Registry ID
    NCT05419401
    Conditions
    Healthy Volunteer
    Interventions
    Capivasertib film-coated tablet, 200 mg; [14C]AZD5363 (Capivasertib)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-04-11
    Completion
    2022-07-12
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteer
    InterventionCapivasertib film-coated tablet, 200 mg; [14C]AZD5363 (Capivasertib)
    PhasePhase 1
    Registry statusCompleted

  • Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

    NCT05008055 · start 2021-11-03

    Registered record
    Registry ID
    NCT05008055
    Conditions
    Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
    Interventions
    Capivasertib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-11-03
    Completion
    2024-10-25
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed or Refractory B-cell Non-Hodgkin Lymphoma
    InterventionCapivasertib
    PhasePhase 2
    Registry statusCompleted

  • A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours

    NCT04958226 · start 2021-10-15

    Registered record
    Registry ID
    NCT04958226
    Conditions
    Solid Tumour
    Interventions
    Capivasertib; Midazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-10-15
    Completion
    2023-02-15
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumour
    InterventionCapivasertib; Midazolam
    PhasePhase 1
    Registry statusCompleted

  • Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants

    NCT04944771 · start 2021-07-26

    Registered record
    Registry ID
    NCT04944771
    Conditions
    Solid and Hematological Malignancies
    Interventions
    Capivasertib; Rabeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-07-26
    Completion
    2022-05-04
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid and Hematological Malignancies
    InterventionCapivasertib; Rabeprazole
    PhasePhase 1
    Registry statusCompleted

  • Capivasertib China PK Study

    NCT04742036 · start 2021-02-22

    Registered record
    Registry ID
    NCT04742036
    Conditions
    Advanced Solid Tumours
    Interventions
    Capivasertib; Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-02-22
    Completion
    2022-07-29
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumours
    InterventionCapivasertib; Paclitaxel
    PhasePhase 1
    Registry statusCompleted

  • A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body

    NCT04712396 · start 2021-02-01

    Registered record
    Registry ID
    NCT04712396
    Conditions
    Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)
    Interventions
    Capivasertib; Itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-02-01
    Completion
    2021-03-25
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)
    InterventionCapivasertib; Itraconazole
    PhasePhase 1
    Registry statusCompleted

  • Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

    NCT04493853 · start 2020-07-13

    Registered record
    Registry ID
    NCT04493853
    Conditions
    Hormone-Sensitive Prostate Cancer
    Interventions
    Capivasertib; Placebo; Abiraterone Acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2020-07-13
    Completion
    2027-03-31
    Enrolment
    1,012

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHormone-Sensitive Prostate Cancer
    InterventionCapivasertib; Placebo; Abiraterone Acetate
    PhasePhase 3
    Registry statusActive not recruiting

  • Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

    NCT04305496 · start 2020-04-16

    Registered record
    Registry ID
    NCT04305496
    Conditions
    Locally Advanced (Inoperable) or Metastatic Breast Cancer
    Interventions
    Fulvestrant; Capivasertib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2020-04-16
    Completion
    2026-06-22
    Enrolment
    818

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocally Advanced (Inoperable) or Metastatic Breast Cancer
    InterventionFulvestrant; Capivasertib; Placebo
    PhasePhase 3
    Registry statusActive not recruiting

  • A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

    NCT04087174 · start 2019-08-05

    Registered record
    Registry ID
    NCT04087174
    Conditions
    Prostate Cancer
    Interventions
    Capivasertib; Enzalutamide; Abiraterone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-08-05
    Completion
    2021-06-22
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionCapivasertib; Enzalutamide; Abiraterone
    PhasePhase 1
    Registry statusCompleted

  • Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

    NCT03997123 · start 2019-06-25

    Registered record
    Registry ID
    NCT03997123
    Conditions
    Triple Negative Breast Neoplasms
    Interventions
    Capivasertib; Paclitaxel; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2019-06-25
    Completion
    2026-03-16
    Enrolment
    923

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTriple Negative Breast Neoplasms
    InterventionCapivasertib; Paclitaxel; Placebo
    PhasePhase 3
    Registry statusActive not recruiting

  • ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

    NCT03903835 · start 2019-02-01

    Registered record
    Registry ID
    NCT03903835
    Conditions
    Metastatic Castration-resistant Prostate Cancer (mCRPC); Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    Interventions
    Enzalutamide Oral Capsule; Abiraterone Oral Tablet; Carboplatin; Cabazitaxel 60 mg Solution for Injection; Docetaxel Injectable Solution; Radium Chloride Ra-223; Niraparib plus Abiraterone acetate plus Prednisone; Capivasertib plus Docetaxel; Apalutamide; Darolutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2019-02-01
    Completion
    2026-12
    Enrolment
    750

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-resistant Prostate Cancer (mCRPC); Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    InterventionEnzalutamide Oral Capsule; Abiraterone Oral Tablet; Carboplatin; Cabazitaxel 60 mg Solution for Injection +6 more
    PhasePhase 3
    Registry statusRecruiting

  • A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

    NCT03742102 · start 2018-12-21

    Registered record
    Registry ID
    NCT03742102
    Conditions
    Triple Negative Breast Neoplasms
    Interventions
    Durvalumab; Capivasertib; Oleclumab; Paclitaxel; Trastuzumab deruxtecan; Datopotamab deruxtecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2018-12-21
    Completion
    2027-02-26
    Enrolment
    243

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTriple Negative Breast Neoplasms
    InterventionDurvalumab; Capivasertib; Oleclumab; Paclitaxel +2 more
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • AMTEC IIT: Phase 2 Multiarm Study in TNBC

    NCT03801369 · start 2018-12-12

    Registered record
    Registry ID
    NCT03801369
    Conditions
    Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma
    Interventions
    Biopsy; Capivasertib; Ceralasertib; Durvalumab; Olaparib; Quality-of-Life Assessment; Selumetinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2018-12-12
    Completion
    2024-12-23
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma
    InterventionBiopsy; Capivasertib; Ceralasertib; Durvalumab +3 more
    PhasePhase 2
    Registry statusTerminated